1)Rowinsky EK, Cazenave LA, Donehower RC:Taxol:a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
2)山田一彦:タキソール包埋アルブミンabraxaneの臨床開発.Drug Delivery System 24:38-44,2009
3)青儀健二郎:アルブミン懸濁型パクリタキセル.臨床腫瘍プラクティス 7:96-99,2011
4)濱口哲弥:ナノテクノロジーを用いたがん治療の現状.癌と化学療法 36:372-376,2009
5)Gradishar WJ, Tjulandin S, Davidson N et al:Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polythylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803, 2005
6)Teitelbaum BA, Tresley DJ:Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80:277-279, 2003
7)Telander DG, Sarraf D:Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22:151-153, 2007
8)Joshi MM, Garreon BR:Paclitaxel maculopathy. Arch Ophthalmol 125:709-710, 2007
9)伊藤 正・奥田正俊:抗癌剤パクリタキセル使用中に囊胞様の黄斑症を呈した1例.日眼会誌 114:23-27,2010
10)冨田有輝・建林美佐子・森本裕子・他:乳癌に対する化学治療中に両眼性黄斑浮腫をきたした1例.臨眼 64:1149-1152,2010
11)太田勲男・片岡信也・平 康二:パクリタキセル黄斑症の1例.旭川赤十字病院医学雑誌 23,24:77-79,2011
12)Smith SV, Benz MS, Brown DM:Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 126:1605-1606, 2008
13)Murphy CG, Walsh JB, Hudis CA et al:Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 28:e684-e687, 2010
14)Baskin DE, Garg SJ:Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab. Can J Ophthalmol 46:200-201, 2011
15)Rahman HT, Yeh S, Bergstrom CS:Cystoid macular edema without leakage secondary to nab-paclitaxel(abraxane):clinical experience with intravitreal bevacizumab. J Ocul Phamacol Ther 29:360-362, 2013
16)Tanaka Y, Bando H, Hara H et al:Cystoid macular edema induced by nab-paclitaxel. Breast Cancer 2012[Epub ahead of print]
17)Esmaeli B, Valero V, Ahmadi MA et al:Canalicular stenosis secondary to docetaxel(taxotere):a newly recognized side effect. Ophthalmology 108:994-995, 2004
18)加藤秀紀・尾本 聡・久保寛之・他:ドセタキセルによって涙道閉塞をきたした3症例.臨眼 58:1463-1466,2004
19)Semb KA, Aamdal S, Oian P:Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426-3432, 1998